All News

ankylosing%20spondylitis.jpg

Secukinumab in Psoriatic Arthritis Patients with Axial Disease

d Sheila Reyes, MD

Results of the MAXIMISE trial show that Secukinumab provided clinical improvement and reduction in inflammatory MRI lesions in patients with psoriatic arthritis and axial disease through week 52. 

Read Article
ACRmtg.jpg (keep)

Industry Abstract Previews - ACR2020

d Jack Cush, MD

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Read Article
Shoutout to @SattuiSEMD and @NavarroMillanMD showing #dementia is lower in #RA pts on bDMARDs compared to csDMARDs using CMS data #ACR20 ABS#0488 @RADoctor @RheumNow https://t.co/1XOV2zqKko
Bella Mehta bella_mehta ( View Tweet)

DISCOVER-2 (52 wk study) Guselkumab 100mg q4wk and q8wk for tx of PsA 1️⃣Sustained responses in: ACR20/50/70, PASI90/100, HAQ-DI, MDA/VLDA, QoL 2️⃣Improvement enthesitis/dactylitis 3️⃣No increase rate of serious infection @RheumNow #ACR20 Abs#0506 https://t.co/7MXYTucVZ9

Robert B Chao, MD doctorRBC ( View Tweet)
IL-6 blockade for management of irAEs without inhibiting anti cancer immune response. Should these be given prior or concomitantly with ICIs? Some interesting ideas to look up from the cancer and immunotherapy study group. #ACR20 @UTSWNews @ACRheum @RheumNow

Adela Castro AdelaCastro222 ( View Tweet)

More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX
Eric Dein ejdein1 ( View Tweet)
What's your initial biologic of choice when escalating therapy for PsA patients non-responsive to csDMARDs? @RheumNow #ACR20

sheila RHEUMarampa ( View Tweet)

Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20

Robert B Chao, MD doctorRBC ( View Tweet)

The Great Debate results! https://t.co/tJk0yIRqfK
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

How would you change csDMARDS and bDMARDS a few days before vaccination - if/when #COVID19 KILLED vaccine comes in (Assuming live vaccine would need strict medication management.) #ACR20 @RheumNow

Bella Mehta bella_mehta ( View Tweet)

DVT/PE has been the sticking point for baricitinib in RA. DVT/PE risk in integrated safety analysis >8y: incidence doesn't increase, but also doesn't decrease. No diff with dose either. Every drug has pros/cons; it's how we manage risk that counts... #ACR20 ABST0202 @RheumNow https://t.co/V88tQjcXSJ
David Liew drdavidliew ( View Tweet)
Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/LfjqZpnGCh
Richard Conway RichardPAConway ( View Tweet)
ACR20 Podcast

QD Clinic Podcast - 106 thru 109

d Jack Cush, MD

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.



In this compilation from the past week we talk about



- HIV and arthritis



- Hyperuricemia in PsA



- An odd kind of dermatomyositis

Read Article
4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6, cirrhosis NNH 1000 5.LoDoCo2: colchicine prevents MACE: NNT 36 6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ: NNH 600

k dao KDAO2011 ( View Tweet)

Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need

Links:

Peter Nash drpnash ( View Tweet)

The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06

Links:

American College of Rheumatology ACRheum ( View Tweet)

Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/

ATS Clinical Problems Assembly ATSCPAssembly ( View Tweet)

infx.pneumonia.jpg

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

d Jack Cush, MD

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

Read Article
Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.